[Pimozide: 16 months of follow-up].
D001714:Bipolar Disorder / Q000188:drug therapy; D056486:Chemical and Drug Induced Liver Injury; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy; D007046:Hysteria / Q000188:drug therapy; D010259:Paranoid Disorders / Q000188:drug therapy; D011247:Pregnancy; D011618:Psychotic Disorders / Q000188:drug therapy*; D011644:Puerperal Disorders / Q000188:drug therapy; D012559:Schizophrenia / Q000188:drug therapy; D014149:Tranquilizing Agents / Q000009:adverse effects / Q000627:therapeutic use*
D014149:Tranquilizing Agents
Le pimozide: seize mois de follow-up.